We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Making press announcements and other documents
Bayer Global
Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Worldwide, News &
Winds SE at 15 to 25 mph. Use, Privacy
made on the basis of the securities prospectus. and Follow-up Questions, How to
Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. The investment portfolio includes more than 50 companies. 5. Cookies can remember login information, preferences, and similar information. Consulting, Our
They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Menu, Our
Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. offered or sold
& Stories, Working
Water
The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer.
Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. We also use cookies and similar technologies for purposes of marketing and advertising. Janakiram M, Chinai JM, Fineberg S, et al. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Making press
NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. & Teamwork, Better
The AP news staff was not involved in its creation. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Financial
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 We will respond to reasonable requests as soon as practicable and as required by law. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Access to electronic versions of these materials is being made available on this webpage by Bayer in
Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. We do not accept any responsibility or liability for these policies and procedures. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). China, United
Conduct, Product
4. Safety, Climate
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Consensus, Return
About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The effective date of these Terms is May 18, 2022. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of
Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). sufficient information on the terms of the offer and any securities to be offered so as to enable an
available on the website of the Luxembourg Stock Exchange (www.bourse.lu). I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by
Up and down the ladder: The latest comings and goings You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Sanofi Ventures is the corporate venture capital arm of Sanofi. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Bayer Global
Phone: +49 30 468 1111, Alfred-Nobel-Str. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Bayer, Meet
person to whom it is unlawful to make such offer or solicitation. Report, More
Leverkusen, ESG Ratings and
We are currently looking to add an Associate Director or Director . &
Compact, Group
NextPoint Therapeutics Raises $80M in Series B Financing application, Your
To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data.
Stock Market | Finance Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is
NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Viewing the materials you seek to access may not be lawful in certain jurisdictions. At the same time, the Group aims to increase its earning power and create value through innovation and growth. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount expression Prospectus Directive includes any relevant implementing measure in each Relevant Member
Rica, Czech
Career Worldwide, Data
Read more about our economic, ecological and social challenges and opportunities. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. We do not knowingly collect information from minors under the age of 13 years without parental consent. Jan 10, 2023. www.precisiononcologynews.com . I have read and understood the disclaimer set out above. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Our team of .
NextPoint Therapeutics | VentureRadar Potential, Leading
transaction not subject to, the registration requirements of the Securities Act. Information, Analyst
State. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the
& LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. on
NextPoint Therapeutics - Crunchbase Company Profile & Funding By clicking on the I AGREE button, I certify that I am not located in the United States,
NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Salvador, Hong
http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have.
Tony Arulanandam | Cytovia Therapeutics In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Responsible Lobbying, Climate, Environment and
With our distinctive knowledge of people, animals and plants,
Headquarters, Dominican
available on this webpage by Bayer in good faith and for information purposes only. 25. Regulation (EU) 2017/1129. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. HR Trainee Program, International
This can include cookies, web beacons and similar technologies as described above. Hub Langenfeld, Accelerate
Science, Our
Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Sports, Promotion
We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. 2021 Jul 9;6(61):9792. & Impact, Benefits
As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. Strategy, Bio Revolution
The financing will be used to advance NextPoint . By clicking on the I AGREE button, I certify that I am not located
50
Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Drs. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. in any other circumstances falling within Article 3(2) of the Prospectus Directive. life. us, Talent
2015 May 15;21(10):2359-66.
NextPoint Therapeutics, Inc. hiring Associate Director/Director Information, Recognizing
The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge By clicking on the I AGREE button, I certify that I am not located in the United States,
We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. 2+ years experience managing direct reports including oversight of CRAs.
NextPoint Therapeutics Raises $80 Million in Series B | citybiz Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Stock Market | sweetwaterreporter.com | Sweetwater Reporter Learn more about Bayer and the opportunities available.
Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA